Your browser is no longer supported. Please, upgrade your browser.
Settings
BCAB [NASD]
BioAtla, Inc.
Index- P/E- EPS (ttm)- Insider Own6.70% Shs Outstand33.66M Perf Week-0.68%
Market Cap1.34B Forward P/E- EPS next Y-2.48 Insider Trans-17.84% Shs Float25.40M Perf Month-3.28%
Income- PEG- EPS next Q-0.58 Inst Own59.20% Short Float13.05% Perf Quarter-17.34%
Sales0.34M P/S3935.04 EPS this Y-24.80% Inst Trans-0.22% Short Ratio16.24 Perf Half Y-6.78%
Book/sh5.82 P/B7.04 EPS next Y-31.20% ROA- Target Price- Perf Year-
Cash/sh6.78 P/C6.05 EPS next 5Y- ROE- 52W Range27.15 - 76.63 Perf YTD20.52%
Dividend- P/FCF- EPS past 5Y- ROI-15.70% 52W High-46.51% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low50.98% ATR2.27
Employees36 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)49.98 Volatility5.01% 5.33%
OptionableYes Debt/Eq0.00 EPS Q/Q30.80% Profit Margin- Rel Volume1.58 Prev Close40.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume204.14K Price40.99
Recom1.60 SMA200.47% SMA50-1.17% SMA200-11.23% Volume321,623 Change1.46%
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jan-11-21Initiated Credit Suisse Outperform $49
Jan-11-21Initiated BTIG Research Buy $47
Jun-14-21 02:03AM  
May-12-21 06:26PM  
Mar-16-21 01:59AM  
Dec-18-20 04:00PM  
Dec-16-20 05:34PM  
04:52PM  
Dec-15-20 07:59PM  
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorJul 15Sale38.2945017,23019,809Jul 19 09:25 PM
SHORT JAY M PHDChief Executive OfficerJun 21Sale39.1355,0002,152,373790,333Jun 22 07:39 PM
SHORT JAY M PHDChief Executive OfficerJun 17Sale39.2219,269755,753845,333Jun 22 07:39 PM
Levy GuyDirectorJun 17Sale39.16400,00015,664,000270,553Jun 21 04:30 PM
Levy GuyDirectorDec 18Buy18.001,388,89025,000,0201,055,557Dec 22 04:30 PM
Cormorant Asset Management, LPFormer 10% OwnerDec 18Buy18.00800,00014,400,0002,292,060Dec 22 04:09 PM